Your shopping cart is currently empty

EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | EP26 is an orally active and potent inhibitor of EGFR and PD-L1, with IC50 values of 48.6 nM and 1.77 µM, respectively. It reduces the protein expression of p-EGFR and induces cell cycle arrest at the G0/G1 phase. EP26 shows potential for glioblastoma research. |
| Targets&IC50 | EGFR:48.6 nM, PD-L1:1.77 μM |
| In vitro | EP26 (0-4 µM; 48 h) reduces p-EGFR protein expression in a dose-dependent manner. At concentrations of 0.5, 1, and 2 µM, EP26 (48 h) induces cell cycle arrest at the G0/G1 phase. Additionally, EP26 binds to human PD-L1 and mouse PD-L1 in a dose-dependent fashion, with K D values of 0.58 and 0.52 µM, respectively. |
| In vivo | EP26 (50, 100 mg/kg; p.o.; once daily for 21 days) demonstrates antitumor activity in mice. |
| Formula | C42H42ClFN4O5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.